NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

I suspect the company may be attempting to deceive shareholders and others about the timing of approvals. It might be wishful thinking that the MHRA approval could be announced sooner than 4Q23. But wouldn’t be surprised if that faux expectation is being disseminated just to lower expectations and to keep everyone off the sent as a product of their profound paranoia. The company did that with the JAMA article by attempting to divert attention away from the publisher by creating the expectation that the article would be published in NEJM.

But if there’s no approval until year end, and nothing occurs with a partnership or listing in the meantime, which seems all tied together as a package, then we’re in for a whole lot of hurt. Maybe to the point of losing some of the investor base that has at least kept the stock price afloat while the number of outstanding shares keep growing, thereby diluting the stock and the value of each share.

Crash has already suggested this is not the stock for weak hands or those that find this company difficult to understand, or lack patience. So I’m not sure where the replacement retail investors will come from if the longer term shareholders begin to unwind some or all of their investment in NWBO.

But I’m a dreamer, so maybe everything will unfold sooner than what’s been currently floated in the blogosphere.

Everyone is lying.